Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial

G Cefalo; M Massimino; Antonio Ruggiero; Giuseppe Barone; Vita Ridola; F Spreafico; P Potepan; Me Abate; M Mascarin; Ml Garrè; G Perilongo; E Madon; Cesare Colosimo; Riccardo Riccardi

doi:10.1093/neuonc/not320

Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial

G Cefalo
, M Massimino
, Antonio Ruggiero
, Giuseppe Barone
, Vita Ridola
, F Spreafico
, P Potepan
, Me Abate
, M Mascarin
, Ml Garrè
, G Perilongo
, E Madon
, Cesare Colosimo
, Riccardo Riccardi^*

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

37 Citazioni (Scopus)

Abstract

The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.

Lingua originale	Inglese
pagine (da-a)	748-753
Numero di pagine	6
Rivista	Neuro-Oncology
Volume	16
Numero di pubblicazione	5
DOI	https://doi.org/10.1093/neuonc/not320
Stato di pubblicazione	Pubblicato - 2014

All Science Journal Classification (ASJC) codes

Oncologia
Neurologia (clinica)
Ricerca sul Cancro

Keywords

medulloblastoma
phase II trial
temozolomide

Accesso al documento

10.1093/neuonc/not320

Altri file e collegamenti

Cita questo

Cefalo, G., Massimino, M., Ruggiero, A., Barone, G., Ridola, V., Spreafico, F., Potepan, P., Abate, M., Mascarin, M., Garrè, M., Perilongo, G., Madon, E., Colosimo, C., & Riccardi, R. (2014). Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. Neuro-Oncology, 16(5), 748-753. https://doi.org/10.1093/neuonc/not320

@article{aa7414d8497e47dab95b813169aa1462,

title = "Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial",

abstract = "The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.",

keywords = "medulloblastoma, phase II trial, temozolomide, medulloblastoma, phase II trial, temozolomide",

author = "G Cefalo and M Massimino and Antonio Ruggiero and Giuseppe Barone and Vita Ridola and F Spreafico and P Potepan and Me Abate and M Mascarin and Ml Garr{\`e} and G Perilongo and E Madon and Cesare Colosimo and Riccardo Riccardi",

year = "2014",

doi = "10.1093/neuonc/not320",

language = "English",

volume = "16",

pages = "748--753",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "5",

}

Cefalo, G, Massimino, M, Ruggiero, A, Barone, G, Ridola, V, Spreafico, F, Potepan, P, Abate, M, Mascarin, M, Garrè, M, Perilongo, G, Madon, E, Colosimo, C & Riccardi, R 2014, 'Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial', Neuro-Oncology, vol. 16, n. 5, pagg. 748-753. https://doi.org/10.1093/neuonc/not320

TY - JOUR

T1 - Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial

AU - Cefalo, G

AU - Massimino, M

AU - Ruggiero, Antonio

AU - Barone, Giuseppe

AU - Ridola, Vita

AU - Spreafico, F

AU - Potepan, P

AU - Abate, Me

AU - Mascarin, M

AU - Garrè, Ml

AU - Perilongo, G

AU - Madon, E

AU - Colosimo, Cesare

AU - Riccardi, Riccardo

PY - 2014

Y1 - 2014

N2 - The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.

AB - The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.

KW - medulloblastoma

KW - phase II trial

KW - temozolomide

KW - medulloblastoma

KW - phase II trial

KW - temozolomide

UR - https://publicatt.unicatt.it/handle/10807/55974

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84899437120&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84899437120&origin=inward

U2 - 10.1093/neuonc/not320

DO - 10.1093/neuonc/not320

M3 - Article

SN - 1522-8517

VL - 16

SP - 748

EP - 753

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - 5

ER -

Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo